Showing posts with label HIV Drugs. Show all posts
Showing posts with label HIV Drugs. Show all posts

Sunday, October 5, 2014

Profiteering with PrEP (PreExposure Prophylaxis). Gilead pharmaceutical company's toxic Truvada for so-called HIV





by Terry Michael, September 30, 2014

I trace how a supplemental use for Gilead's HIV chemotherapy went from confirmation-biased clinical trials, funded by Dr. Anthony Fauci, NIH/NIAID director; to approval by the FDA, in a corrupt "user fee" (funded by Gilead) fast-tracked process, just in time for Fauci to announce it at the International AIDS Society "XIX AIDS Conference" in Washington, DC, in July 2012; to the CDC's  compliant  endorsement in May 2014; and now is being touted by a science-uninformed mass media and gay press, heavily promoted by the Gilead public relations machine.



America’s AIDS czar for almost 30 years, Dr. Anthony Fauci has promoted and shepherded human experimental research that has exposed HIV negative Third World men and women to toxic chemotherapy, many already health-challenged from lack of clean water, poor sanitation, malnutrition and old diseases like tuberculosis and malaria. The experiments were to demonstrate “Pre-Exposure Prophylaxis” (PrEP) for the anti-viral drug Truvada. Like other nucleoside analogs, Truvada has well-assessed adverse (“side”) effects. Funded with tax dollars and non-profit grants, including tens of millions from Fauci’s National Institute of Allergy and Infectious Diseases, as well as from the CDC and USAID, studies have accrued to the sole benefit of a politically well- connected U.S. drug corporation, Gilead, the only company to “donate” pills for the clinical trials. 

When PrEP was discussed initially in mainstream media, including in a New York Times articlepublished January 22, 2006 (later critically reviewed by independent journalist Liam Scheff), human guinea pigs, almost all impoverished Third World subjects, were already in early phase trials, designed to produce results that would allow Gilead eventually to seek FDA approval for re- purposing its “Viread” but later only its “Truvada” chemotherapy for use by HIV antibody negative Americans, for theoretical protection from a virus proclaimed by the U.S. government in 1984 as a discrete pathogen responsible for the amorphous health condition described since 1982 as “acquired immune deficiency syndrome,” or “AIDS.” Under patent protection until 2021, Truvada remains more profitable for Gilead than Viread, for which a generic can be sold as early as December 2016. 

Wednesday, August 6, 2014

Black market for "lifesaving HIV treatments"

The Washington Post

Watchdog: Some Medicare spending on HIV drugs appear questionable in 2012 audit 
By Charles Ornstein

"Medicare spent more than $30 million in 2012 on questionable HIV medication costs, the inspector general of the Department of Health and Human Services said in a report set for release Wednesday.

The report offers a litany of possible fraud schemes, all paid for by Medicare’s prescription drug program known as Part D."

 Medicare paid over $30 million in fraud schemes to thieves re-sell the "lifesaving treatments."  

The only thing missed is that every penny Medicare, Medicaid, ADAP, the VA, etc pays for "ARVs" is a gigantic fraud for worthless, dangeorus toxic chemotherapy.--Terry Michael

In Detroit, a 77-year-old woman purportedly filled $33,500 worth of prescriptions for 10 different HIV medications. But there’s no record that she had HIV or that she had visited the doctors who wrote the scripts.

A 48-year-old in Miami went to 28 pharmacies to pick up HIV drugs worth nearly $200,000, almost 10 times what average patients get in a year. The prescriptions were supposedly written by 16 health providers.

And on a single day, a third patient received $17,500 worth of HIV drugs ­ and none the rest of the year. She acquired more than twice the recommended dose of five HIV drug ingredients.

Tuesday, January 29, 2013

FDA-APPROVED HIV TESTS pt 9


Calypte HIV-1 Urine EIA
False positive results occur more frequently when testing urine specimens compared to blood specimens... Supplemental testing of repeatedly reactive urine specimens should be performed using only the Cambridge HIV-1 Western Blot Kit before the HIV-1 status of an individual can be determined.

All the FDA-APPROVED HIV TESTS Here
*credit to omsj.org  for this list

Thursday, January 17, 2013

FDA-APPROVED HIV TESTS pt 7


ARCHITECT HIV Ag/Ab Combo
The ARCHITECT HIV Ag/Ab Combo assay result and supplemental assay results should be interpreted in conjunction with the patient’s clinical presentation, history, and other laboratory results... An individual who has antibodies to HIV is presumed to be infected with the virus... Clinical correlation is indicated with appropriate counseling, medical evaluation... to determine whether a diagnosis of HIV infection is accurate.



All the FDA-APPROVED HIV TESTS Here
*credit to omsj.org  for this list


Tuesday, January 15, 2013

FDA-APPROVED HIV TESTS pt 6

Abbott Prism HIV O-Plus
The presence of HIV-1 and/or HIV-2 antibodies is not a diagnosis of AIDS... A person who has antibodies to HIV-1 is presumed to be infected with the virus... Clinical correlation is indicated with appropriate counseling, medical evaluation, and possibly additional testing to decide whether a diagnosis of HIV infection is accurate.

All the FDA-APPROVED HIV TESTS Here
*credit to omsj.org  for this list

Sunday, January 13, 2013

FDA-APPROVED HIV TESTS pt 8


Bio-Rad Multispot HIV-1/HIV-2 Rapid Test
A person who has antibodies to HIV-1 is presumed to be infected with the virus... Clinical correlation is indicated... to decide whether a diagnosis of HIV infection is accurate.
RECALL 6 June 2008 – The typographical error will be corrected for future shipments of Multispot.
RECALL 13 May 2004 – Software error was contained on the ETI-LAB Applications disk for programming the BioRad HIV-1/HIV-2 Plus O assay. The error induced specimen and conjugate incubation temperatures for the assay to remain at ambient temperature rather than the required 37°C temperature.





All the FDA-APPROVED HIV TESTS Here
*credit to omsj.org  for this list

Wednesday, December 5, 2012

Antiretroviral treatment for HIV reduces food insecurity, reports AIDS Journal

 Public release date: 4-Dec-2012

Antiretroviral treatment for HIV reduces food insecurity, reports AIDS Journal

By increasing work ability, anti-HIV drugs may reduce hunger as well as improve health

Philadelphia, Pa. (December 4, 2012) – Can treatment with modern anti-HIV drugs help fight hunger for HIV-infected patients in Africa? Starting antiretroviral therapy for HIV reduces "food insecurity" among patients in Uganda, suggests a study published online by the journal AIDS, official journal of the International AIDS Society.AIDS is published by Lippincott Williams & Wilkins, a part ofWolters Kluwer Health.
.
Treatment including antiretroviral therapy (ART) may lead to a "positive feedback loop" whereby improved functioning and productivity lead to increased ability to work—and thus to decreased food insecurity, according to the study by Kartika Palar, PhD and colleagues of University of California Los Angeles and RAND Corporation. The article is available on the AIDS journal homepage and in the November 28 print edition.

Monday, December 3, 2012

My journey with HIV has been complex, varied and challenging, by Johnny Trifun


reposted from immunity.org.uk

I recently received a request to fill in a research questionnaire done by a Masters Student in Health Psychology, in association with the Hospital relating to HIV/AIDS patients. The results were printed in the gay press and the results outlined that few patients use Internet to access information on HIV treatments and ‘how few challenge their physician or pose questions regarding treatment’

At first I was pleased that research was being done, I feel Health Psychology plays a major role in the path of HIV/AIDS, however after several attempts to fill in the form, eventually out of frustration, I discarded it. I found the questionnaire failed to acknowledge the complexities of the virus, as well as the complexities and journeys of individuals, to create a more true and meaningful result, or even assess trends and therefore was unable to fill out the form and tick the boxes in a way where I felt that I was being true to myself and helpful to the study. The findings of the research were presented at a recent Body Positive seminar, and one recognized physician pointed out, 'there is no expectation of a cure for HIV in the foreseeable future'. I question this by asking, ”Is it because the whole HIV/AIDS does not exist in the threshold of which we have all believed it to be?”

Saturday, December 1, 2012

Will a so-called "functional" cure be enough to keep HIV in check

 - www.theatlantic.com
As scientists and advocates push beyond merely managing HIV infection with expensive and toxic prescription medications, an overarching question is: Will a so-called "functional" cure be enough to keep HIV in check, such that people with the virus can go months between medical treatments? Or is a truly "sterilizing" cure -- a complete and provable eradication of all traces of HIV -- the only goal worth pursuing?

Saturday, November 17, 2012

Gilead Presents Encouraging Data - HIV therapy Stribild

FOLLOW THE MONEY

Posted
11/16/2012 1:00 PM
 by Zacks Equity Research


Gilead Sciences(GILD) recently presented encouraging long-term data on its HIV therapy Stribild from two ongoing phase III studies (102 and 103) as a first-line therapy. Data from study 102 revealed that Stribild was non-inferior to Gilead's Atripla after two years of treatment.

Data from study 103 demonstrated the non inferiority of Stribild to Norvir (ritonavir)-boosted Reyataz plus Truvada after a similar time period. While Norvir is marketed byAbbott Labs(ABT), Reyataz is marketed byBristol-Myers Squibb(BMY). Gilead presented the encouraging results at the 11th international congress on drug therapy regarding HIV infection in the UK.

We note that Stribild, a combination pill, is a new addition to Gilead's formidable HIV franchise. The drug was approved by the US Food and Drug Administration (FDA) in August 2012 as a first-line therapy for treating adults suffering from HIV. The approval was based on encouraging 48 weeks data from studies 102 and 103. Stribild is under review for the same indication in the EU.

Neutral on Gilead

We currently have a Neutral recommendation on Gilead. The stock carries a Zacks #3 Rank (Holdrating) in the short run. We remain optimistic on the growth prospects of Gilead's HIV drugs, Truvada and Atripla. We are also encouraged by the sales ramp of Complera/Eviplera, which together with Stribild, has further fortified the HIV franchise and helped to mitigate the impact of upcoming patent expirations.

Gilead is looking to combat the threat of genericization by inking deals, making acquisitions and introducing new products. To further strengthen its hepatitis C virusportfolio, Gilead purchased Pharmasset earlier in the year, for approximately $11.1 billion.

Tuesday, October 9, 2012

Share your story on a new Website: Living Without HIV Drugs


Living without HIV drugs

This website is dedicated to the true-life stories of people who have two important things in common:
  • 1. We have all been diagnosed as HIV-Positive at some point in our lives, and
  • 2. We have all stopped, or never started taking the HIV medications normally prescribed by our doctors and clinics and hospitals, and are living healthy, happy lives.
We want to share our stories with you, in hopes that they can be an inspiration and provide you with the hope that you, too, can live without HIV drugs and their very serious and damaging side effects.

Monday, October 8, 2012

More Truths about Truvada: it's a combined HIV drug comprising Emtriva and Viread

sharing this page from Carl Grinde's Blog:
 Now, for the first time, adults who do not have HIV but are at risk of becoming infected can take a medication to reduce the risk of sexual transmission of the virus.
Truvada is made by Gilead.

http://www.gilead.com/pr_933190157
Truvada is made by Gilead. Side effects: "new or worsening kidney problems, thinning of the bones (osteopenia), which could lead to fractures, inflammation, diarrhea, dizziness, nausea, headache, fatigue, abnormal dreams, sleeping problems, rash, depression, changes in the distribution of body fat, stomach area (abdomen) pain, headache, a buildup of acid in the blood (lactic acidosis), decreased weight, Serious liver problems (hepatotoxicity), with liver enlargement (hepatomegaly), and fat in the liver (steatosis). Symptoms of liver problems include your skin or the whites of your eyes turning yellow (jaundice), dark colored urine, light colored stools, lack of appetite, nausea, and/or pain in your lower stomach area. In some cases, these serious conditions have lead to death." 
Quotes from www.truvada.com 

Monday, October 1, 2012

Fears over Aids 'miracle pill": Truvada

MARIKA HILL at www.stuff.co.nz
Fears are being raised that a ''magic pill'' could spark a new wave of the Aids epidemic in Auckland.
The HIV treatment drug Truvada is being touted as a way to protect against infection in the United States and local AIDs campaigners fear this false promise will lead to complacency about safe sex.

Tuesday, September 4, 2012

The Shame of Gilead

by Terry Michael


Gilead Sciences, headquartered in Foster City, CA, is the world's number one purveyor of the chemotherapies known as "anti-retrovirals" (ARVs.) In 2011, the company (named for the Biblical "balm of Gilead") reported ARV sales of about $6.91 billion dollars. The trade names for their ARVs are: Truvada, Atripla, Viread, Complera and Emtriva--all of which they acknowledge have serious adverse "side" effects (as noted in the Gilead prescribing information for Truvada.) Gilead was way ahead of nearest competitor Bristol-Myers-Squibb, which sold about $3.05 billion of the chemo in 2011, according to year-end corporate reports I have reviewed.

Wednesday, August 22, 2012

"If you have a good immune system, then your body can naturally get rid of HIV" asked of Francoise Barre-Sinoussi


Terry Michael asks Francoise Barre-Sinoussi what she thinks about Luc Montagnier's statement:



Dr. Luc Montagnier: “We can be exposed to HIV many times without being chronically infected. Our immune system will get rid of the virus within a few weeks, if you have a good immune system.”

Interviewer: If you have a good immune system, then your body can naturally get rid of HIV?

Dr. Luc Montagnier: Yes.

Interviewer: If you take a poor African, who’s been infected and you build up their immune system, is it possible for them to also naturally get rid of it?

Dr. Luc Montagnier: I would think so.

Interviewer: That’s an important…

Dr. Luc Montagnier: It’s important knowledge which is completely neglected. People always think of drugs and vaccine.

Interviewer: There is no money in nutrition, right?

Dr. Luc Montagnier: There is no profit, yes.

Video captured at the XIX International AIDS Conference in Washington, DC July 26, 2012.
Video credit: Kaiser Family Foundation-funded

Monday, July 30, 2012

AIDS Conference, protestors staged a “die-in” against Gilead Sciences

Posted by Sunny Bjerk

During the International AIDS Conference last week, protestors staged a “die-in” against Gilead Sciences—manufacturer of the HIV/AIDS medication Truvada—holding signs stating, Truvada Pricing is Murder, and_ Gilead: Greed Destroys Access to Care_, among many others. The protest was a very loud and very visible criticism of the pharmaceutical giant, particularly the difference that Truvada costs overseas and in the U.S.—$500 versus $11,000 respectively—as well the luxurious compensation of its CEO, John C. Martin.
This protest demonstrates two very important things. One, that AIDS activism is still very much alive, much to the fear of some; and two, that the InternationalAIDS Conference, its attendees, and its sponsors, have a very complicated relationship.

Thursday, July 26, 2012

Hair samples from infants show exposure to anti-HIV drugs in the womb and during breast-feeding

Researchers from the University of California, San Francisco (UCSF) and Makerere University in Uganda have used hair and blood samples from three-month old infants born to HIV-positive mothers to measure the uninfected babies' exposure—both in the womb and from breast-feeding—to antiretroviral medications their mothers were taking. The results, they said, are surprising
.

"We found high levels of exposure to three antiretroviral medications in the hair samples of HIV uninfected infants at twelve weeks of life," said study senior author, Monica Gandhi, MD, MPH, associate professor of medicine at the UCSF Division of HIV/AIDS at San Francisco General Hospital and Trauma Center (SFGH). "From looking at plasma level data at the same time point, we believe that transfer of two of the medicines from mother to baby occurs exclusively in the womb and transfer of the third medication occurs both in the womb and through breastfeeding."

View the film "Positively False"


 Positively False - Birth of a Heresy traces the challenge over the past 25 years to the scientific orthodoxy which maintains that HIV is the cause of AIDS. Joan Shenton reaches back to 1987 through her extensive archive of broadcast and non-broadcast video material and combines it with current footage. She shows how dissident scientists, journalists and activists have voiced their concerns about the way the infectious hypothesis for AIDS took over from the toxic one and highlights the impact the dogma surrounding a viral cause for AIDS has had on people's lives. The film travels through Africa, Europe and the United States revealing the way plague terror, financial objectives and scientific skullduggery have led to tragic examples of toxicity and death from antiviral drugs, social stigma, broken families, fear of sex, homophobia and imprisonment. Positively False - Birth of a Heresy is produced by Meditel Productions Ltd and The Immunity Resource Foundation in association with Yellow Productions.

Tuesday, July 17, 2012

WHAT HIV DRUGS DO

by Henry Bauer

The previous post (OFFICIAL GUIDELINES FOR HIV TREATMENT, 14 December 2007) offered some extracts from the text of the official Guidelines for treating “HIV-1 infected” people, even when they don’t feel ill and are not visibly ill. The Guidelines also have detailed Tables listing the frequent and serious “side” effects of antiretroviral drugs.
The scare quotes are around “side” to emphasize how evasive a euphemism this is. Molecules, chemicals, drugs can’t choose to do only what we want them to do. Any foreign substance disturbs our physiology, which is an intricate system of balances and feedbacks where any one change is likely to induce others as well. The more powerful a molecule, the more likely it is to disrupt our metabolism in multiple ways. Antiretroviral drugs are extremely powerful molecules that can kill cells and block receptors and incapacitate enzymes. As in cancer chemotherapy, antiretroviral treatment kills or disables innocent as well as guilty cells.
All examples in the following are taken from the 1 December 2007 version of the Treatment Guidelines.

Wednesday, July 4, 2012

Predictability of a CD4 Count


Predictability of a CD4 Count

When an AIDS doctor declares that a patient with a CD4 count is “severely immunesuppressed”
he is making a prediction based on the CD4 count with near certainty. When
a doctor proclaims that an HIV positive person’s CD4 count of 200 or 350 or 500 shows
that it is “time to start drugs” they are also making a prediction on the basis of a CD4
count, a prediction with implied certainty. Perhaps, if pressed, the doctor might admit that
there are some people with low CD4 counts who are not sick, but the basic message is
that CD4 counts have been shown, scientifically, to be highly accurate indicators of your
stage of “progression to AIDS” – from asymptomatic to pre-AIDS (“AIDS-related
complex”) to full-blown AIDS and then death.
But, what is the evidence that CD4 counts are associated with stage of immune
suppression? And, how accurate would a prediction that a certain CD4 count indicates
that a person is at a particular stage of HIV or AIDS be?